ArticleJournal of diabetes and metabolic disorders2026
Dysregulated indoleamine 2,3-dioxygenase contributes to metabolic syndrome.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Dysregulation of tryptophan (Trp) metabolism, specifically changes in Kynurenine (Kyn) and indoleamine 2,3-dioxygenase (IDO) activity, has been associated with the initiation of chronic inflammation, oxidative stress, insulin resistance, and metabolic syndrome (MetS). This study aimed to evaluate the connection between the IDO activity, lipid profile, and oxidative stress with the risk of MetS. Methods: This study was conducted on 140 women, including subjects with MetS ( Results: The levels of FPG, triglycerides, uric acid, insulin, HOMA-IR, Kyn, IDO activity, and IMA were significantly higher in the MetS group compared to non-MetS subjects. Multiple regression analyses showed that uric acid ( Conclusion: The findings demonstrate that IDO activity increases in MetS participants. Additionally, due to the high specificity and sensitivity of IDO activity and TG/HDL-C, they can serve as prognostic biomarkers for MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.